These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 26937194)

  • 21. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
    Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
    Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
    Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
    Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review.
    Bennett JW; Lewis JS; Ellis MW
    Ther Clin Risk Manag; 2008 Feb; 4(1):31-40. PubMed ID: 18728718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
    Dunne MW; Talbot GH; Boucher HW; Wilcox M; Puttagunta S
    Drug Saf; 2016 Feb; 39(2):147-57. PubMed ID: 26715497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The times they are a-changin': new antibacterials for skin and skin structure infections.
    Tran MC; Naumovski S; Goldstein EJ
    Am J Clin Dermatol; 2015 Jun; 16(3):137-46. PubMed ID: 25906205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of clinical evidence for dalbavancin].
    Rodríguez-Pardo D
    Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():33-37. PubMed ID: 28129819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.
    Raad I; Darouiche R; Vazquez J; Lentnek A; Hachem R; Hanna H; Goldstein B; Henkel T; Seltzer E
    Clin Infect Dis; 2005 Feb; 40(3):374-80. PubMed ID: 15668859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study.
    Ioannou P; Wolff N; Mathioudaki A; Spanias C; Spernovasilis N; Kofteridis DP
    Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.
    Seltzer E; Dorr MB; Goldstein BP; Perry M; Dowell JA; Henkel T;
    Clin Infect Dis; 2003 Nov; 37(10):1298-303. PubMed ID: 14583862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
    Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
    Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series.
    Garbo V; Condemi A; Albano C; Polara VF; Parrino R; Macaluso A; Venuti L; Colomba C
    Infez Med; 2024; 32(2):231-240. PubMed ID: 38827834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
    Pfaller MA; Mendes RE; Duncan LR; Flamm RK; Sader HS
    J Antimicrob Chemother; 2018 Oct; 73(10):2748-2756. PubMed ID: 29982565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
    Belley A; Lalonde Seguin D; Arhin F; Moeck G
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bactericidal activity and resistance development profiling of dalbavancin.
    Goldstein BP; Draghi DC; Sheehan DJ; Hogan P; Sahm DF
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1150-4. PubMed ID: 17220411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of dalbavancin in skin and soft tissue infections.
    Bassetti M; Peghin M; Carnelutti A; Righi E
    Curr Opin Infect Dis; 2018 Apr; 31(2):141-147. PubMed ID: 29298166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.
    Dimopoulou D; Mantadakis E; Koutserimpas C; Samonis G
    Antibiotics (Basel); 2023 Sep; 12(10):. PubMed ID: 37887193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in Pediatrics: Insights from Continuation Therapy Experience.
    Scarano SM; Bruzzese E; Poeta M; Del Bene M; Guarino A; Lo Vecchio A
    Antibiotics (Basel); 2024 Apr; 13(4):. PubMed ID: 38667003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection in Patients With Obesity or Diabetes: A Subgroup Analysis of Pooled Phase 3 Clinical Trials.
    Riccobene T; Lock J; Lyles RD; Georgiades B; Nowak M; Gonzalez PL; Park J; Rappo U
    Open Forum Infect Dis; 2023 Jun; 10(6):ofad256. PubMed ID: 37305839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.